402 - 6190 Agronomy Road
About Precision NanoSystemsPrecision NanoSystems, Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI's proprietary NanoAssemblr platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology.
CEO: James Taylor, PhD
COO: Euan Ramsay, PhD
19 articles with Precision NanoSystems
PNI will handle development of the vaccine and CanSinoBIO will take care of preclinical testing, human clinical trials, regulatory submissions and commercialization.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine
Precision NanoSystems to Prese CanSinoBIO will license in Precision NanoSystems' proprietary RNA vaccine platform technology Precision NanoSystems will lead RNA vaccine formulation development CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials TIANJIN, China and VANCOUVER , May 20, 2020 /PRNewswire/ - CanSino Biologics Inc. (Ca
Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr platform for scale-up and GMP manufacturing of nanomedicines
Precision NanoSystems, Inc. (PNI) and Entos Pharmaceuticals (Entos) today announced they have entered into a license and supply agreement whereby PNI will provide its scale-up system, technology transfer and support the GMP manufacturing of Entos' lead candidate.
Precision NanoSystems Announces Manufacturing Collaboration Agreement with Ajinomoto Bio-Pharma Services for GMP Manufacturing of High Quality Nanomedicines
Precision Nanosystems Inc. (PNI), a global leader in innovative solutions for the discovery, development and manufacture of novel nanoparticles medicines, announced today that it has entered into a manufacturing collaboration agreement with Ajinomoto Bio-Pharma Services
Precision NanoSystems (PNI) announced that it has closed a US$6M Series B investment.
Precision NanoSystems Announces Collaboration Agreement with Evonik Canada for the Manufacturing of High Quality Nanomedicines
Precision Nanosystems Inc. (PNI), announced that they have entered into a manufacturing collaboration agreement with Evonik Canada.
Learn how PNI is leading the charge in providing an accessible solution for the discovery and development of molecularly tailored & targeted medicines at the upcoming Bloom Burton & Co. Healthcare Investor Conference scheduled for Wednesday, May 2 - Thursday, May 3, 2018.
Precision NanoSystems Technology Included in Newly Opened Non-Coding RNA Precision Diagnostics and Therapeutics Core Facility
This new facility is dedicated to the study of ncRNA, which play an important role in regulating gene expression and are important for understanding, detecting, and treating disease.
Precision NanoSystems is one of the fastest growing businesses in British Columbia (BC) according to the recently published Top 100 fastest-growing companies in BC list from business news journal Business in Vancouver (BIV).
Precision NanoSystems is one of the fastest growing businesses in British Columbia according to the recently published Top 100 fastest-growing companies in BC list from business news journal Business in Vancouver.
Precision NanoSystems New Headquarters Designed To Enhance Product And Service Offerings To Customers Developing Novel Nanomedicines
Precision NanoSystems To Advance Large-Scale Production Of Nanoparticles With Its NanoAssemblr Blaze System
Precision NanoSystems Launches Innovative Product To Support mRNA And CRISPR/Cas9 Therapeutic Development